Landec Corporation provided consolidated revenue guidance for full year fiscal 2022. For full year fiscal 2022, the company expected consolidated revenues: range of $179 million to $185 million (+4% to +8%).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.79 USD | +0.35% | -8.60% | -7.27% |
Apr. 19 | Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report | MT |
Apr. 01 | Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.27% | 176M | |
+32.06% | 694B | |
+29.39% | 593B | |
-1.46% | 371B | |
+20.10% | 331B | |
+7.30% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.38% | 169B |
- Stock Market
- Equities
- LFCR Stock
- News Lifecore Biomedical, Inc.
- Landec Corporation Provides Consolidated Revenue Guidance for Full Year Fiscal 2022